TABLE 1.
Baseline characteristics of cases and matched controls
| Cases (n = 24) | Controls (n = 64) | p‐Value | |
|---|---|---|---|
| Mean days since inclusion to bleeding event/matching date (SD) | 91.8 (93.8) | 90.1 (92.7) | .94 |
| Mean age, years (SD) | 66.3 (11.5) | 63.4 (12.2) | .33 |
| Male sex, n (%) | 19 (79.2) | 41 (64.1) | .27 |
| Upper gastro‐intestinal cancer, n (%) | 7 (29.2) | 16 (25) | .69 |
| Esophagus | 4 (16.7) | 10 (15.7) | |
| Stomach | 3 (12.5) | 6 (4.4) | |
| Hepatobiliary and pancreatic cancer, n (%) | 4 (16.7) | 11 (17.2) | .95 |
| Pancreas | 2 (8.3) | 8 (12.5) | |
| Cholangiocarcinoma | 1 (4.2) | 2 (3.1) | |
| Gall bladder | 1 (4.2) | 0 | |
| Liver | 1 (1.6) | 1 (4.2) | |
| Lower gastro‐intestinal cancer, n (%) | 14 (48.3) | 37 (57.8) | .96 |
| Colon | 4 (16.7) | 22 (34.3) | |
| Rectum | 8 (33.3) | 15 (23.4) | |
| Body weight at baseline, kg (SD) | 80.3 (16.3) | 79.3 (17.9) | .82 |
| Antiplatelet therapy at baseline, n (%) | 1 (4.2) | 5 (7.8) | .90 |
| Concomitant use of P‐glycoprotein inhibitors, n (%) | 1 (4.2) | 1 (1.6) | .47 |
| Reduced‐dose edoxaban, n (%) | 6 (25) | 15 (23.4) | 1.00 |
| Mean platelet count × 109/L (SD) | 192 (115) | 213 (110) | .44 |
| Mean creatinine clearance in ml/min (SD) a | 91 (30.9) | 108 (51.1) | .13 |
Abbreviation: SD, standard deviation.
a
Calculated with the Cockroft and Gault formula.